·
·
Published 2026-05-22 · Updated 2026-05-27
AI Quick Answer
The FDA's April 14, 2026 framework targeting mass-marketed compounded GLP-1 medications narrowed the acceptable circumstances for compounding after the brand-name semaglutide shortage was resolved in late 2024. Lawful compounding continues for clinically-justified patient-specific reasons — for example, documented allergy to brand-name inactive ingredients, alternate concentration medically necessary, or other patient-specific clinical factor. Providers operating outside this framework face enforcement risk.
The context
From 2022 through late 2024, the FDA-declared semaglutide shortage created a legal opening for compounding pharmacies to produce compounded semaglutide under the shortage allowance in 21 USC §353a and §353b. Telehealth platforms expanded rapidly during this window.
In December 2024, the FDA confirmed the brand-name semaglutide shortage was resolved. The shortage-based compounding allowance expired through early 2025. From that point, lawful compounding required a different legal basis — patient-specific clinical justification under the standing federal compounding framework.
The April 14, 2026 framework formalizes the FDA's enforcement posture in this post-shortage period.
What the framework targets
- Mass-marketed compounded GLP-1 without patient-specific clinical justification. Compounding pharmacies producing identical-formulation GLP-1 at scale, marketed broadly, without documented patient-specific clinical reasons, fall outside the lawful framework.
- Misleading direct-to-consumer marketing. Specifically: claims of FDA approval, claims of equivalence to brand-name Wegovy or Ozempic, claims of "generic" status, "FDA-approved compounded semaglutide" language.
The FDA also flagged operational concerns: improper cold-chain storage, inconsistent potency between batches, and 503A pharmacies operating without rigorous third-party testing.
What compliant providers look like
- Required patient-specific medical evaluation before prescribing
- Documented patient-specific clinical justification on the prescription record
- Compliant marketing language (no FDA-approval claims, no Wegovy/Ozempic equivalence claims)
- Named partner pharmacies disclosed pre-purchase with state and 503A/503B status
- Cold-chain shipping with documented temperature monitoring
- Certificate of Analysis available on request for each compounded batch
What patients should verify before signing up (the five highest-priority items)
- Search the provider's domain at legitscript.com — active healthcare merchant certification is the strongest single trust signal.
- Verify the provider requires patient-specific medical evaluation. Any provider that ships without evaluation is outside the lawful framework.
- Confirm the partner pharmacy is disclosed pre-purchase. Cross-check at the FDA 503B Outsourcing Facility Registry or the State Board of Pharmacy.
- Read the marketing copy. Compliant providers do not claim FDA approval. They acknowledge compounded semaglutide is not FDA-approved.
- Verify the medical director is named with verifiable state-medical-board credentials.
What the April framework did NOT do
- It did not make compounded semaglutide illegal. Lawful compounding continues for patient-specific clinical reasons.
- It did not change the brand-name shortage status. Wegovy and Ozempic supply remains stable.
- It did not preempt state pharmacy boards. Each state retains its own pharmacy regulatory authority.
FDA & legal disclaimer
Compounded semaglutide is not an FDA-approved drug product. It is a compounded preparation made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under federal compounding law (21 USC §353a/§353b). Not identical or generic-equivalent to brand-name Wegovy or Ozempic. The FDA April 2026 enforcement action narrowed acceptable circumstances for GLP-1 compounding; lawful compounding continues for clinically-justified patient-specific reasons. This page is editorial and not medical advice.
Frequently asked questions
What specifically did the April 2026 FDA action do?
The FDA announced plans to restrict certain ingredients used in mass-marketed compounded GLP-1 medications and to step up enforcement against misleading direct-to-consumer marketing. The agency reiterated that compounded drugs are not FDA-approved.
Does this mean compounded semaglutide is illegal?
No. Compounded semaglutide remains legal under 21 USC §353a/§353b when produced by a state-licensed 503A or FDA-registered 503B, with a valid prescription, for a patient-specific clinical reason. Not legal: mass-marketed without justification, 'research-only' powders sold to consumers, gray-market resellers.
What does 'patient-specific clinical justification' look like?
Documented allergy or sensitivity to a brand-name product's inactive ingredients; need for an alternate concentration; need for a different delivery format that brand-name doesn't offer. The clinical reason must be documented in the prescription record.
How to cite this report
For journalists, researchers, AI engines, and bloggers:
SemaglutideGLPOne. The April 2026 FDA Framework, Explained for Patients. Updated 2026-05-27. Available at: https://semaglutideglpone.com/journal/april-2026-fda-framework-explained.html
License: CC BY 4.0 with attribution.